SOSV

Oxyle AG is a Swiss company based in Zurich that specializes in wastewater treatment aimed at removing persistent and toxic micropollutants from water sources. Established in 2020, the company has developed a novel technology that effectively degrades hazardous substances, including pharmaceuticals, personal-care products, endocrine-disrupting chemicals, pesticides, and industrial chemicals. Oxyle serves a diverse clientele, including the pharmaceutical, biotech, chemical, food and beverage sectors, research laboratories, hospitals, and wastewater treatment facilities. Its innovative approach not only helps clients comply with regulatory standards but also offers a sustainable alternative to wastewater incineration, thereby contributing to reduced CO2 emissions.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

VisusNano Ltd. is a pre-clinical company based in London, United Kingdom, focused on developing a drug-eluting intraocular lens implant for cataract surgery. Founded in 2016, the company aims to enhance patient outcomes by reducing the risks associated with cataract procedures, such as intraocular inflammation, infection, and opacification. This innovative lens technology eliminates the need for postoperative eye drops and laser treatments, positioning it as a potential game-changer in both human and veterinary cataract surgery markets. Through its advancements, VisusNano seeks to revolutionize the standard of care in ophthalmic procedures.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

BryoSphere is a company specializing in the manufacturing of specialty chemicals, employing moss plants and biotechnology methods in the production of their goods. The company is currently focused on the development of two key products: one for addressing skin hyperpigmentation in topical treatments, and another as an anti-cancer drug.

Xias Bio is a biotechnology startup focused on producing recombinant proteins that enhance the delivery of functional ingredients for various sectors, including research, beauty, and healthcare. The company specializes in developing non-immunogenic natural motifs, which provide a superior platform for creating soluble and active ingredients with desirable properties such as improved gel and film formation and antioxidant effects. By offering an adaptable, animal product-free biomaterial, Xias Bio delivers tailored biological functionalities that outperform traditional synthetic and animal-based products. This innovation enables pharmaceutical and cosmetic companies to access non-toxic, non-immunogenic alternatives for a wide range of applications.

Allozymes is a deep technology company that specializes in ultrahigh-throughput microfluidics technology to enhance enzyme evolution and development. It focuses on creating sensitive and accurate assays for enzymatic reactions, alongside proprietary microfluidic chips and proteomics technologies. By employing molecular biology and process engineering, Allozymes aims to produce pure enzymes tailored for specific applications. This innovative platform enables clients to expedite custom enzyme development and to create novel, sustainable natural products.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Artyc specializes in providing sustainable cold shipping solutions for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers designed to decarbonize the cold chain, thereby fostering a more sustainable logistics industry. By utilizing these innovative containers, businesses can benefit from reduced shipping costs and enhanced temperature monitoring throughout their logistics operations, ensuring the safe and efficient transport of temperature-sensitive goods.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

Kolibri is a biotechnology company focused on addressing the challenges of large-scale cell culture, which is crucial for the accessibility and affordability of cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that utilizes innovative techniques in acoustics and biology. This platform features bioreactors designed to grow cells efficiently using acoustic waves, resulting in a yield increase of up to 90 times while significantly reducing production costs by up to 50 times. By enhancing the bioproduction of biologics, Kolibri aims to facilitate patient access to gene therapies and next-generation vaccines, thereby contributing to advancements in drug development and healthcare.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

FluoSphera is a company focused on the development of innovative drugs that minimize adverse side effects and reduce reliance on animal testing. By addressing the complexities of human physiological responses, FluoSphera aims to assist organizations in creating safer pharmaceuticals and protecting populations from harmful compounds. Their approach emphasizes efficiency in drug discovery, ultimately enhancing public health and safety.

Bioeutectics focuses on creating environmentally friendly industrial products by providing high-performance, natural solvents. Utilizing proprietary eutectic technology, the company produces solvents that mimic the natural processes of plants, using 100% renewable resources. This innovation allows Bioeutectics to replace traditional petrochemical solvents in various industrial applications, promoting sustainability. Their product line caters to diverse sectors, including food, pharmaceuticals, and personal care, and is designed to be non-toxic, biodegradable, and customizable to meet specific industry needs. Through these advancements, Bioeutectics aims to lead the market in offering sustainable alternatives that enhance environmental responsibility in industrial processes.

VisusNano Ltd. is a pre-clinical company based in London, United Kingdom, focused on developing a drug-eluting intraocular lens implant for cataract surgery. Founded in 2016, the company aims to enhance patient outcomes by reducing the risks associated with cataract procedures, such as intraocular inflammation, infection, and opacification. This innovative lens technology eliminates the need for postoperative eye drops and laser treatments, positioning it as a potential game-changer in both human and veterinary cataract surgery markets. Through its advancements, VisusNano seeks to revolutionize the standard of care in ophthalmic procedures.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Mazlite is a developer of an industrial IoT platform focused on spray monitoring and digitization in hazardous environments. The company provides unique hardware sensors and web-based software that facilitate real-time analytics and cloud-based data management. This technology is particularly beneficial for industries such as automotive paint and pharmaceuticals, allowing manufacturers to monitor spray applications effectively. By utilizing a physics-based artificial intelligence system, Mazlite enables manufacturers to identify and resolve product quality issues, enhance sustainability, and reduce material and energy waste, ultimately minimizing scraps and repairs.

Oxyle AG is a Swiss company based in Zurich that specializes in wastewater treatment aimed at removing persistent and toxic micropollutants from water sources. Established in 2020, the company has developed a novel technology that effectively degrades hazardous substances, including pharmaceuticals, personal-care products, endocrine-disrupting chemicals, pesticides, and industrial chemicals. Oxyle serves a diverse clientele, including the pharmaceutical, biotech, chemical, food and beverage sectors, research laboratories, hospitals, and wastewater treatment facilities. Its innovative approach not only helps clients comply with regulatory standards but also offers a sustainable alternative to wastewater incineration, thereby contributing to reduced CO2 emissions.

FluoSphera is a company focused on the development of innovative drugs that minimize adverse side effects and reduce reliance on animal testing. By addressing the complexities of human physiological responses, FluoSphera aims to assist organizations in creating safer pharmaceuticals and protecting populations from harmful compounds. Their approach emphasizes efficiency in drug discovery, ultimately enhancing public health and safety.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Spindle Biotech Inc., founded in 2017 and based in Toronto, Canada, specializes in the development of synthetic RNA. The company is focused on commercializing a proprietary RNA polymerase that facilitates large-scale production of mRNA vaccines. Recent advancements in mRNA technology underscore the significance of synthetic RNA, particularly for its transient properties. Spindle Biotech also employs enzymes and microfluidic technology to create high-fidelity RNA arrays, which are designed for high-throughput applications in RNP-based CRISPR and RNA screening. These innovations enable biotechnology companies to utilize synthetic RNA in gene editing and drug discovery, positioning Spindle Biotech as a key player in the evolving landscape of biotechnology.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

Bioeutectics focuses on creating environmentally friendly industrial products by providing high-performance, natural solvents. Utilizing proprietary eutectic technology, the company produces solvents that mimic the natural processes of plants, using 100% renewable resources. This innovation allows Bioeutectics to replace traditional petrochemical solvents in various industrial applications, promoting sustainability. Their product line caters to diverse sectors, including food, pharmaceuticals, and personal care, and is designed to be non-toxic, biodegradable, and customizable to meet specific industry needs. Through these advancements, Bioeutectics aims to lead the market in offering sustainable alternatives that enhance environmental responsibility in industrial processes.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

Pregenerate, Inc. is a company focused on developing organ-on-a-chip technology to replace animal testing in medical and pharmaceutical research, specifically for arthritis treatments. Founded in 2019 and incorporated in Delaware, Pregenerate offers scalable models that utilize human cells, allowing pharmaceutical companies to enhance drug development efficiency and reduce costs significantly. This innovative approach not only improves the success rates of bringing drugs to market but also enables the stratification of patients into targeted treatment subgroups. Ultimately, Pregenerate's technology aims to provide personalized treatment recommendations for individuals based on their specific arthritis needs, thereby advancing the field of personalized medicine in healthcare.

Artyc specializes in providing sustainable cold shipping solutions for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers designed to decarbonize the cold chain, thereby fostering a more sustainable logistics industry. By utilizing these innovative containers, businesses can benefit from reduced shipping costs and enhanced temperature monitoring throughout their logistics operations, ensuring the safe and efficient transport of temperature-sensitive goods.

Artyc specializes in providing sustainable cold shipping solutions for the biotech, pharmaceutical, and medical sectors. The company manufactures refrigerant-free, reusable, active cooling containers designed to decarbonize the cold chain, thereby fostering a more sustainable logistics industry. By utilizing these innovative containers, businesses can benefit from reduced shipping costs and enhanced temperature monitoring throughout their logistics operations, ensuring the safe and efficient transport of temperature-sensitive goods.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Synthace Limited is a company focused on transforming the way biological experimentation is conducted across various sectors, including health, pharmaceuticals, food, energy, agri-science, and industrial biotechnology. Established in 2011 and headquartered in London, with an additional office in Cambridge, Massachusetts, Synthace offers a cloud-based platform called Antha. This platform enables life science research and development teams to streamline their experimental processes by allowing scientists to design, plan, and execute reproducible experiments without requiring coding skills. Antha facilitates the automation of laboratory experiments and the organization of experimental data, making it easier for researchers to run complex experiments that might have been previously deemed impractical. The company has also formed a strategic partnership with Microsoft to enhance its offerings.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

RxAll, Inc. is engaged in developing an artificial intelligence-based pharmacy platform that focuses on the authentication and distribution of pharmaceuticals in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) system for real-time drug authentication. Its platform employs a molecular sensor device along with a cloud database containing spectral signatures of various medicines, allowing for non-destructive verification prior to fulfilling pharmacy orders. This technology helps in identifying counterfeit drugs and provides pharmaceutical companies with timely information regarding product authenticity. By streamlining the process of delivering authenticated medicines to hospitals, pharmacies, and patients, RxAll aims to enhance access to high-quality medications while addressing the issue of drug counterfeiting.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

Allozymes is a deep technology company that specializes in ultrahigh-throughput microfluidics technology to enhance enzyme evolution and development. It focuses on creating sensitive and accurate assays for enzymatic reactions, alongside proprietary microfluidic chips and proteomics technologies. By employing molecular biology and process engineering, Allozymes aims to produce pure enzymes tailored for specific applications. This innovative platform enables clients to expedite custom enzyme development and to create novel, sustainable natural products.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Pregenerate, Inc. is a company focused on developing organ-on-a-chip technology to replace animal testing in medical and pharmaceutical research, specifically for arthritis treatments. Founded in 2019 and incorporated in Delaware, Pregenerate offers scalable models that utilize human cells, allowing pharmaceutical companies to enhance drug development efficiency and reduce costs significantly. This innovative approach not only improves the success rates of bringing drugs to market but also enables the stratification of patients into targeted treatment subgroups. Ultimately, Pregenerate's technology aims to provide personalized treatment recommendations for individuals based on their specific arthritis needs, thereby advancing the field of personalized medicine in healthcare.

Kolibri is a biotechnology company focused on addressing the challenges of large-scale cell culture, which is crucial for the accessibility and affordability of cell and gene therapies, as well as clean meat production. The company has developed a proprietary cell-engineering platform that utilizes innovative techniques in acoustics and biology. This platform features bioreactors designed to grow cells efficiently using acoustic waves, resulting in a yield increase of up to 90 times while significantly reducing production costs by up to 50 times. By enhancing the bioproduction of biologics, Kolibri aims to facilitate patient access to gene therapies and next-generation vaccines, thereby contributing to advancements in drug development and healthcare.

Synthace Limited is a company focused on transforming the way biological experimentation is conducted across various sectors, including health, pharmaceuticals, food, energy, agri-science, and industrial biotechnology. Established in 2011 and headquartered in London, with an additional office in Cambridge, Massachusetts, Synthace offers a cloud-based platform called Antha. This platform enables life science research and development teams to streamline their experimental processes by allowing scientists to design, plan, and execute reproducible experiments without requiring coding skills. Antha facilitates the automation of laboratory experiments and the organization of experimental data, making it easier for researchers to run complex experiments that might have been previously deemed impractical. The company has also formed a strategic partnership with Microsoft to enhance its offerings.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

Wayfinder Biosciences is a biotechnology company based in Seattle, WA, focused on developing orally available small molecule drugs that target RNA to address key disease areas such as oncology and neurodegenerative disorders. Established in 2021, the company employs a proprietary platform that integrates advanced screening technologies and computational methods to efficiently discover potent and selective RNA-targeting molecules. By leveraging high-throughput screening combined with machine learning and unique datasets, Wayfinder aims to enable the development of drugs for traditionally inaccessible targets, thus addressing significant unmet medical needs in genetic diseases, cancer, and other conditions.

Allozymes is a deep technology company that specializes in ultrahigh-throughput microfluidics technology to enhance enzyme evolution and development. It focuses on creating sensitive and accurate assays for enzymatic reactions, alongside proprietary microfluidic chips and proteomics technologies. By employing molecular biology and process engineering, Allozymes aims to produce pure enzymes tailored for specific applications. This innovative platform enables clients to expedite custom enzyme development and to create novel, sustainable natural products.

Microbiome-focused therapeutics for diseases of the oral cavity and their systemic effects

RxAll, Inc. is engaged in developing an artificial intelligence-based pharmacy platform that focuses on the authentication and distribution of pharmaceuticals in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) system for real-time drug authentication. Its platform employs a molecular sensor device along with a cloud database containing spectral signatures of various medicines, allowing for non-destructive verification prior to fulfilling pharmacy orders. This technology helps in identifying counterfeit drugs and provides pharmaceutical companies with timely information regarding product authenticity. By streamlining the process of delivering authenticated medicines to hospitals, pharmacies, and patients, RxAll aims to enhance access to high-quality medications while addressing the issue of drug counterfeiting.

AsimicA is focused on developing innovative technologies aimed at enhancing production efficiency in microbial biosynthetic factories. Founded in November 2018 by Nikolai Mushnikov and Grant Bowman, the company addresses the challenge of low yields in biosynthetic processes, a significant limitation in biotechnology. By utilizing microbial stem cell technology, AsimicA's solutions have the potential to significantly boost biomolecule production in the pharmaceutical industry, enabling biotech companies to achieve several-fold increases in the productivity of their biofactories. This advancement could revolutionize the industry by improving the overall efficiency and effectiveness of biosynthetic production.

Cayuga develops novel hemostatic drugs and devices using biomimetic polyphosphate technology to control bleeding and accelerate healing.

Pregenerate, Inc. is a company focused on developing organ-on-a-chip technology to replace animal testing in medical and pharmaceutical research, specifically for arthritis treatments. Founded in 2019 and incorporated in Delaware, Pregenerate offers scalable models that utilize human cells, allowing pharmaceutical companies to enhance drug development efficiency and reduce costs significantly. This innovative approach not only improves the success rates of bringing drugs to market but also enables the stratification of patients into targeted treatment subgroups. Ultimately, Pregenerate's technology aims to provide personalized treatment recommendations for individuals based on their specific arthritis needs, thereby advancing the field of personalized medicine in healthcare.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

ANA Therapeutics Inc. is a biotechnology company focused on the research and development of niclosamide-based vaccines and therapeutics aimed at treating COVID-19. Founded in 2020 and headquartered in Foster City, California, the company is developing a proprietary formulation of niclosamide, which is designed to help medical practitioners effectively treat patients afflicted with the coronavirus. ANA Therapeutics is actively conducting human clinical trials to evaluate the efficacy of its product, ANA001, which comes in the form of capsules. The company's mission is to address the challenges posed by the coronavirus pandemic and contribute to patient care and recovery.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

BrightCure Ltd. is a company based in London, United Kingdom, that specializes in developing probiotic-based therapies aimed at treating urinary tract infections (UTIs). Founded in 2019, BrightCure addresses the significant challenge of recurrent and difficult-to-treat UTIs, which affect a large portion of the global population, particularly women. Conventional UTI treatments often fall short in effectiveness and can lead to serious side effects, contributing to the rise of antibiotic-resistant infections. The company focuses on leveraging the natural microbiome to eliminate harmful bacteria while restoring beneficial flora. BrightCure's flagship product, a bioactive intimate cream, is designed to enhance the natural immune response and support urinary tract health. The UTI treatment market is projected to grow significantly, reflecting the urgent need for effective solutions. BrightCure has received recognition for its innovative approach, including seed investment from SOSV and accolades in various competitions, underscoring its potential impact in the healthcare sector.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

ANA Therapeutics Inc. is a biotechnology company focused on the research and development of niclosamide-based vaccines and therapeutics aimed at treating COVID-19. Founded in 2020 and headquartered in Foster City, California, the company is developing a proprietary formulation of niclosamide, which is designed to help medical practitioners effectively treat patients afflicted with the coronavirus. ANA Therapeutics is actively conducting human clinical trials to evaluate the efficacy of its product, ANA001, which comes in the form of capsules. The company's mission is to address the challenges posed by the coronavirus pandemic and contribute to patient care and recovery.

Renegade.bio is a biotechnology startup focused on creating and implementing high throughput diagnostics for the detection of novel infectious diseases. The company specializes in developing innovative diagnostics and assays that aid in drug development, utilizing advanced techniques such as biomarker discovery, polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid chromatography-mass spectrometry (LC-MS). This expertise enables healthcare organizations to offer diagnostic testing across various settings, including individuals, workplaces, schools, communities, events, concerts, and festivals.

RxAll, Inc. is engaged in developing an artificial intelligence-based pharmacy platform that focuses on the authentication and distribution of pharmaceuticals in Africa. Founded in 2015 and headquartered in New Haven, Connecticut, the company utilizes a deep learning hyperspectral Internet of Things (IoT) system for real-time drug authentication. Its platform employs a molecular sensor device along with a cloud database containing spectral signatures of various medicines, allowing for non-destructive verification prior to fulfilling pharmacy orders. This technology helps in identifying counterfeit drugs and provides pharmaceutical companies with timely information regarding product authenticity. By streamlining the process of delivering authenticated medicines to hospitals, pharmacies, and patients, RxAll aims to enhance access to high-quality medications while addressing the issue of drug counterfeiting.

Synthace Limited is a company focused on transforming the way biological experimentation is conducted across various sectors, including health, pharmaceuticals, food, energy, agri-science, and industrial biotechnology. Established in 2011 and headquartered in London, with an additional office in Cambridge, Massachusetts, Synthace offers a cloud-based platform called Antha. This platform enables life science research and development teams to streamline their experimental processes by allowing scientists to design, plan, and execute reproducible experiments without requiring coding skills. Antha facilitates the automation of laboratory experiments and the organization of experimental data, making it easier for researchers to run complex experiments that might have been previously deemed impractical. The company has also formed a strategic partnership with Microsoft to enhance its offerings.

Valanx Biotech GmbH, founded in 2017 and located in Klosterneuburg, Austria, specializes in the development and manufacture of synthetic programmable amino acids, particularly Norl. The company has created SnapIt, a reactive amino acid that facilitates the conjugation of antibodies with medicines, resulting in antibody-drug conjugates aimed at treating cancer. In addition to cancer therapy, Valanx's products are utilized for PEGylation of therapeutic peptides and proteins, as well as for the directed and oriented immobilization of biocatalysts and biosensors. The company also offers on-demand bioanalytics and mass spectrometry services. Valanx Biotech's site-specific protein conjugation platform aims to streamline the development of protein-drug conjugates, making the process faster and more cost-effective, ultimately allowing healthcare providers to produce receptor proteins with specific chemical modifications.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

Allozymes is a deep technology company that specializes in ultrahigh-throughput microfluidics technology to enhance enzyme evolution and development. It focuses on creating sensitive and accurate assays for enzymatic reactions, alongside proprietary microfluidic chips and proteomics technologies. By employing molecular biology and process engineering, Allozymes aims to produce pure enzymes tailored for specific applications. This innovative platform enables clients to expedite custom enzyme development and to create novel, sustainable natural products.

Sothic Bioscience Ltd. is a biotech company based in Cork, Ireland, established in 2015. The company focuses on developing LimuleX, a bio-production platform designed to create bio-identical replacements for naturally sourced limulus amebocyte lysate. This innovation aims to eliminate the reliance on the threatened horseshoe crab species in the pharmaceutical quality control supply chain. Sothic Bioscience is currently in the lab bench production phase of a highly specific pyrogen contamination testing reagent. To support scaling up production and market entry, the company is actively raising seed capital, emphasizing its commitment to replacing unsustainable animal sourcing with scalable production of high-quality biomolecules for the pharmaceutical, medical device, and biomedical research sectors.

Intrinsic Medicine, Inc. is a clinical-stage company focused on the research and development of innovative medicines aimed at improving patient health. Formerly known as Lupa Bio, Inc., it was established in 2018 and is headquartered in Des Moines, Washington. The company specializes in developing prebiotic drugs, particularly Human Identical Milk Oligosaccharides (HiMOs), which are designed to treat various human diseases. These HiMOs are formulated to remain stable in stomach acid and resist degradation by enzymes in the upper gastrointestinal tract, thereby promoting gut health and modulating immune responses. As a virtual company, Intrinsic Medicine leverages a technical and operational platform to efficiently and ethically bring these important medicines to patients.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

Bioprocol is a company founded in 2004 that specializes in producing natural materials derived from ethically sourced plants within Colombia's rich biodiversity. Utilizing scientifically validated methods, Bioprocol develops raw materials for the pharmaceutical, cosmetic, and nutraceutical industries. The company's offerings are aimed at enhancing health, beauty, and well-being, particularly through the creation of skincare products designed to restore and improve skin quality. By focusing on sustainable practices, Bioprocol not only supports the conservation of Colombian biodiversity but also contributes to the development of high-value innovations in various sectors.

BioSapien is a pre-clinical biotechnology company focused on creating innovative biodegradable implantable products for oncology applications. The company is developing a 3D-printed drug delivery platform that utilizes a biodegradable mesh to deliver active pharmaceutical ingredients (APIs) directly to tumor sites, thereby minimizing systemic side effects associated with traditional therapies. Their flagship product, the MediChip, is designed to administer FDA-approved high-dose systemic therapies in a localized and sustained manner, enhancing the quality of patient care. Current research is focused on applications for pancreatic and lung cancers, with plans to expand the pipeline to include other types such as colorectal, breast, and stomach cancers. By targeting drug delivery directly to cancerous tissues, BioSapien aims to improve treatment efficacy while reducing toxicity for patients.

CyCa OncoSolutions Pvt. Ltd. is a technology company focused on developing molecular devices for the targeted delivery of anticancer drugs directly into cells. Established in 2017 and based in Balasore, India, the company has created innovative drug delivery systems that can cross cellular membrane bilayers, facilitating the introduction of functional molecules such as anticancer agents, water-soluble dyes, and imaging agents into the cytoplasm and other organelles. This technology is particularly beneficial for pharmaceutical and biotechnology companies, as it enhances the brand lifecycle of their drugs and molecules by improving delivery efficacy.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

Spindle Biotech Inc., founded in 2017 and based in Toronto, Canada, specializes in the development of synthetic RNA. The company is focused on commercializing a proprietary RNA polymerase that facilitates large-scale production of mRNA vaccines. Recent advancements in mRNA technology underscore the significance of synthetic RNA, particularly for its transient properties. Spindle Biotech also employs enzymes and microfluidic technology to create high-fidelity RNA arrays, which are designed for high-throughput applications in RNP-based CRISPR and RNA screening. These innovations enable biotechnology companies to utilize synthetic RNA in gene editing and drug discovery, positioning Spindle Biotech as a key player in the evolving landscape of biotechnology.

Serenity Bioworks is focused on developing innovative therapies that address significant gaps in healthcare, particularly in the fields of gene therapy and targeted protein degradation. The company creates antibody mimetics aimed at enhancing the process of targeted protein degradation by integrating advanced display techniques with computational methods to optimize discovery. Additionally, Serenity is working on gene therapies designed to treat conditions such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. These therapies are designed to improve patient outcomes by enabling healthcare providers to enhance the efficacy and safety profiles of treatments, ultimately leading to safer and more durable solutions for patients.

Pregenerate, Inc. is a company focused on developing organ-on-a-chip technology to replace animal testing in medical and pharmaceutical research, specifically for arthritis treatments. Founded in 2019 and incorporated in Delaware, Pregenerate offers scalable models that utilize human cells, allowing pharmaceutical companies to enhance drug development efficiency and reduce costs significantly. This innovative approach not only improves the success rates of bringing drugs to market but also enables the stratification of patients into targeted treatment subgroups. Ultimately, Pregenerate's technology aims to provide personalized treatment recommendations for individuals based on their specific arthritis needs, thereby advancing the field of personalized medicine in healthcare.

Biospin is an introducing a revolutionary microbial detection system that provides gold standard detection of pathogens for F&B, water, consumer goods and pharmaceutical products in real time.

Synthace Limited is a company focused on transforming the way biological experimentation is conducted across various sectors, including health, pharmaceuticals, food, energy, agri-science, and industrial biotechnology. Established in 2011 and headquartered in London, with an additional office in Cambridge, Massachusetts, Synthace offers a cloud-based platform called Antha. This platform enables life science research and development teams to streamline their experimental processes by allowing scientists to design, plan, and execute reproducible experiments without requiring coding skills. Antha facilitates the automation of laboratory experiments and the organization of experimental data, making it easier for researchers to run complex experiments that might have been previously deemed impractical. The company has also formed a strategic partnership with Microsoft to enhance its offerings.

Hexafly is a biotechnology company based in Kells, Ireland, that focuses on developing sustainable products derived from the farming of Black Soldier Fly larvae. Established in 2016, Hexafly operates within the circular economy by converting food waste into valuable resources, including insect oil and protein for aquaculture and animal feed, as well as Frass, a plant nutrition compound. The company also produces Chitin, a biopolymer used in pharmaceuticals, cosmetics, and food additives. By offering these products online, Hexafly aims to provide sustainable solutions for the aquaculture, animal feed, and plant nutrition industries, contributing to a more sustainable food system for animals and, ultimately, humans.

VisusNano Ltd. is a pre-clinical company based in London, United Kingdom, focused on developing a drug-eluting intraocular lens implant for cataract surgery. Founded in 2016, the company aims to enhance patient outcomes by reducing the risks associated with cataract procedures, such as intraocular inflammation, infection, and opacification. This innovative lens technology eliminates the need for postoperative eye drops and laser treatments, positioning it as a potential game-changer in both human and veterinary cataract surgery markets. Through its advancements, VisusNano seeks to revolutionize the standard of care in ophthalmic procedures.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

NewPath Probiotics is a Chicago-based company that specializes in manufacturing probiotic medicine specifically designed for the treatment of sinus-related issues. Founded in 2018, the company offers a product known as New Path Probiotics Sinus Rinse, which aims to alleviate symptoms associated with sinus problems and address sinus microbes. By focusing on organic and natural ingredients, NewPath Probiotics provides an alternative to traditional over-the-counter nasal steroids, allowing customers to manage congestion through a more natural approach.